Jeff Benjamin “There are some midtier biotech firms with terrific pipelines,” said Steven Roge, a portfolio manager with R.W. Roge & Co. Inc., which has $200 million under management. For example, he estimates Genzym’s fair-value price to be about $55, or about $5 above its current share price. “A larger company might pay $70 or...Read More